Appointment dossier — Mucinous Ovarian Tumors
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Mucinous Ovarian Tumors
Compounds named in the cited literature for Mucinous Ovarian Tumors, labeled by the strongest evidence found:
- anti-HER2 therapy — Named in the literature
- appendectomy — Named in the literature
- appendicectomy — Named in the literature
- capecitabine and oxaliplatin — Named in the literature
- carboplatin and paclitaxel — Named in the literature
- mirvetuximab soravtansine (MIRV) — Named in the literature
- PARP inhibitors — Named in the literature
- PD-1/PD-L1 inhibitors — Named in the literature
- primary cytoreductive surgery — Named in the literature
Open recruiting trials (18)
- NCT06399757 · Phase 1 / Phase 2 — A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (United States)
- NCT07488676 · Phase 1 / Phase 2 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (United States)
- NCT05512208 · Phase 2 — A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (United States)
- NCT06687070 · Phase 1 — APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST (China)
- NCT06778863 · Phase 1 — A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation (United States)
- NCT06458712 · Phase 1 — Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies (United States)
- NCT04282044 · Phase 1 — Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (United States)
- NCT05427487 · Phase 1 — Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (Australia)
- NCT06276491 · Phase 1 — Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (United States)
- NCT05659381 · Phase 3 — Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (United States)
- NCT05123807 · Phase 2 — Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) (United States)
- NCT05112601 · Phase 2 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (United States)
- NCT04804007 · Phase 2 — Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT (United States)
- NCT05961124 · Phase 2 — Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer (Canada)
- NCT05128825 · Phase 2 — A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (United States)
- NCT03878849 · Phase 2 — Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer (United States)
- NCT06690775 · Phase 2 — CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (United States)
- NCT06971744 · Phase 2 — Autophagy Maintenance (AUTOMAIN) (United States)
Most-relevant first: trials that name Mucinous Ovarian Tumors, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT06399757), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?